MX2015013703A - Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas. - Google Patents

Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas.

Info

Publication number
MX2015013703A
MX2015013703A MX2015013703A MX2015013703A MX2015013703A MX 2015013703 A MX2015013703 A MX 2015013703A MX 2015013703 A MX2015013703 A MX 2015013703A MX 2015013703 A MX2015013703 A MX 2015013703A MX 2015013703 A MX2015013703 A MX 2015013703A
Authority
MX
Mexico
Prior art keywords
tl1a
inflammation
treating fibrosis
inhibiting
individual
Prior art date
Application number
MX2015013703A
Other languages
English (en)
Spanish (es)
Inventor
Q Shih David
R Targan Stephan
Li Dalin
Bilsborough Janine
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51625529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015013703(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of MX2015013703A publication Critical patent/MX2015013703A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
MX2015013703A 2013-03-27 2014-03-27 Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas. MX2015013703A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361805806P 2013-03-27 2013-03-27
US201361872020P 2013-08-30 2013-08-30
PCT/US2014/032054 WO2014160883A1 (en) 2013-03-27 2014-03-27 Treating fibrosis and inflammation by inhibiting tl1a

Publications (1)

Publication Number Publication Date
MX2015013703A true MX2015013703A (es) 2016-08-11

Family

ID=51625529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013703A MX2015013703A (es) 2013-03-27 2014-03-27 Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas.

Country Status (11)

Country Link
US (3) US10633449B2 (enExample)
EP (3) EP3639841B1 (enExample)
JP (4) JP6671276B2 (enExample)
KR (4) KR20240122922A (enExample)
CN (2) CN112870368A (enExample)
AU (1) AU2014241162A1 (enExample)
BR (1) BR112015024752A2 (enExample)
CA (1) CA2908553A1 (enExample)
CL (1) CL2015002866A1 (enExample)
MX (1) MX2015013703A (enExample)
WO (1) WO2014160883A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
US10633449B2 (en) 2013-03-27 2020-04-28 Cedars-Sinai Medical Center Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN104745587B (zh) * 2015-01-05 2017-07-21 西安交通大学医学院第一附属医院 用于识别结缔组织生长因子的核酸适配子及其应用
US20180156781A1 (en) * 2015-05-15 2018-06-07 Cedars-Sinai Medical Center Models, methods and compositions for treating inflammatory bowel disease
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
JP7475811B2 (ja) 2016-05-20 2024-04-30 シーダーズ―シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
WO2021202926A1 (en) * 2020-04-02 2021-10-07 La Jolla Institute For Immunology Methods and combinations for dual targeting of tnf family members
WO2021247770A1 (en) * 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Methods and systems for measuring post-operative disease recurrence
EP4665395A1 (en) * 2023-02-17 2025-12-24 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the liver
WO2025038473A1 (en) 2023-08-11 2025-02-20 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use

Family Cites Families (339)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4265823A (en) 1979-01-04 1981-05-05 Robert E. Kosinski Aurothiosteroids
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60174629A (ja) 1984-02-20 1985-09-07 Mitsubishi Monsanto Chem Co 二軸延伸されたポリアミドフイルムの製造方法
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US4935234A (en) 1987-06-11 1990-06-19 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US5219997A (en) 1987-07-06 1993-06-15 Dana-Farber Cancer Institute Monoclonal antibody which inhibits the adhesion functions of the β integrin, CR3
US5114842A (en) 1987-07-08 1992-05-19 The Scripps Research Institute Peptides and antibodies that inhibit platelet adhesion
US4925572A (en) 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US4880548A (en) 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5235049A (en) 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
US5002873A (en) 1989-03-17 1991-03-26 Fred Hutchinson Cancer Research Center DNA sequence encoding a lymphocyte adhesion receptor for high endothelium
US5091302A (en) 1989-04-27 1992-02-25 The Blood Center Of Southeastern Wisconsin, Inc. Polymorphism of human platelet membrane glycoprotein iiia and diagnostic and therapeutic applications thereof
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5137806A (en) 1989-12-11 1992-08-11 Board Of Regents, The University Of Texas System Methods and compositions for the detection of sequences in selected DNA molecules
US5264554A (en) 1990-01-19 1993-11-23 The Blood Center Of Southeastern Wisconsin, Inc. Platelet cell adhesion molecule and variants thereof
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
WO1992002819A2 (en) 1990-08-10 1992-02-20 The Regents Of The University Of California Assay for ulcerative colitis and primary sclerosing cholangitis
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5085318A (en) 1990-11-19 1992-02-04 Leverick Kathy L Secured disc folder
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
CA2110387A1 (en) 1991-06-11 1992-12-23 Antonin R. Defougerolles Intercellular adhesion molecule-3 and its binding ligands
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5227369A (en) 1991-07-11 1993-07-13 The Regents Of The University Of California Compositions and methods for inhibiting leukocyte adhesion to cns myelin
US5234810A (en) 1991-09-20 1993-08-10 The United States Of America As Represented By The Secretary Of Agriculture Diagnostic assays for genetic mutations associated with bovine leukocyte adhesion deficiency
WO1993007485A1 (en) 1991-10-10 1993-04-15 The Regents Of The University Of California Rare immunoglobulin framework regions associated with human disease
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
GB9126918D0 (en) 1991-12-19 1992-02-19 Univ London Members of specific binding pairs;methods of their making and using
US5236081A (en) 1992-01-31 1993-08-17 Shape Inc. Compact disc package
ATE161192T1 (de) 1992-08-21 1998-01-15 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
US5263743A (en) 1992-09-25 1993-11-23 Pharmagraphics, Inc. Package label
ATE173630T1 (de) 1992-12-29 1998-12-15 Genentech Inc Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
ES2148251T3 (es) 1993-03-10 2000-10-16 Cedars Sinai Medical Center Metodos para detectar selectivamente anticuerpos anticitoplasma de neutrofilos perinucleares de la colitis ulcerosa o colangitis esclerosante primaria.
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
GB9307503D0 (en) 1993-04-13 1993-06-02 Kodak Ltd Method of making a photographic developer solution
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US5681699A (en) 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
WO1995031575A1 (en) 1994-05-17 1995-11-23 Cedars-Sinai Medical Center Methods of screening for crohn's disease using tnf microsatellite alleles
US5494920A (en) 1994-08-22 1996-02-27 Eli Lilly And Company Methods of inhibiting viral replication
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
US5691151A (en) 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
JP4046349B2 (ja) 1994-11-07 2008-02-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 腫瘍壊死因子−γ
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
WO2000066608A1 (en) 1999-04-30 2000-11-09 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6599719B2 (en) 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US6824767B2 (en) 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US20030129189A1 (en) 1994-11-07 2003-07-10 Guo-Liang Yu Tumor necrosis factor-gamma
JPH08248832A (ja) 1995-03-06 1996-09-27 Mita Ind Co Ltd 画像形成装置
US5518488A (en) 1995-03-20 1996-05-21 Schluger; Allen CD holder of cardboard and method of construction
US5607879A (en) 1995-06-28 1997-03-04 Taiwan Semiconductor Manufacturing Company Ltd. Method for forming buried plug contacts on semiconductor integrated circuits
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US5840300A (en) 1995-09-11 1998-11-24 Trustees Of The University Of Pennsylvania Methods and compositions comprising single chain recombinant antibodies
US5942390A (en) 1996-01-12 1999-08-24 Cedars-Sinai Medical Center Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US5590769A (en) 1996-03-20 1997-01-07 Lin; Shi-Ping Individual CD case
WO1997035589A1 (en) 1996-03-26 1997-10-02 Kopreski Michael S Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US6025539A (en) 1996-04-09 2000-02-15 Mayo Foundation For Medical Education And Research IL-5 transgenic mouse
US5874233A (en) 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
AU2438397A (en) 1996-04-12 1997-11-07 Cedars-Sinai Medical Center Methods of determining the risk of pouchitis development
US5916748A (en) 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US5683698A (en) 1996-08-02 1997-11-04 New England Deaconess Hospital Formulation for alleviating symptoms associated with arthritis
JPH1078528A (ja) 1996-09-03 1998-03-24 Fujitsu Ltd 光合分波器及び波長分割多重モジュール
US6034102A (en) 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6114395A (en) 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US7514232B2 (en) 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
US20040013664A1 (en) 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
ES2286843T3 (es) 1997-01-14 2007-12-01 Human Genome Sciences, Inc. Receptores 6 alfa y 6 beta del factor de necrosis tumoral.
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US6197928B1 (en) 1997-03-14 2001-03-06 The Regents Of The University Of California Fluorescent protein sensors for detection of analytes
US5968741A (en) 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6183951B1 (en) 1997-04-11 2001-02-06 Prometheus Laboratories, Inc. Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
US20030129215A1 (en) 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US20020006613A1 (en) 1998-01-20 2002-01-17 Shyjan Andrew W. Methods and compositions for the identification and assessment of cancer therapies
US6607879B1 (en) 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
WO1999045959A1 (en) 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
US5947281A (en) 1998-07-06 1999-09-07 Kaneff; Mitchell S. Unfolding disc holder
US20050123938A1 (en) 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
CA2267481A1 (en) 1999-03-30 2000-09-30 Gabriel Pulido-Cejudo Critical interdependency: from the role of estrogen on breast cancer to the susceptibility of women towards hiv infection
US6539374B2 (en) 1999-06-03 2003-03-25 Microsoft Corporation Methods, apparatus and data structures for providing a uniform representation of various types of information
WO2000076492A1 (en) 1999-06-15 2000-12-21 Nutri-Logics, Inc. Nutrient formulations for disease reduction, and related treatment and component screening methods
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US20030204075A9 (en) 1999-08-09 2003-10-30 The Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US6376176B1 (en) 1999-09-13 2002-04-23 Cedars-Sinai Medical Center Methods of using a major histocompatibility complex class III haplotype to diagnose Crohn's disease
US6762042B2 (en) 1999-12-09 2004-07-13 Merck & Co., Inc. DNA molecules encoding human NHL a DNA helicase
EP1276899A2 (en) 1999-12-10 2003-01-22 Whitehead Institute For Biomedical Research Ibd-related polymorphisms
US6869762B1 (en) 1999-12-10 2005-03-22 Whitehead Institute For Biomedical Research Crohn's disease-related polymorphisms
US20020165137A1 (en) 2000-01-31 2002-11-07 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2393002A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001064856A2 (en) 2000-02-28 2001-09-07 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
US6348316B1 (en) 2000-04-12 2002-02-19 Cedars-Sinai Medical Center Genetic testing for determining the risk of pouchitis development
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1286664B1 (en) 2000-05-12 2007-07-25 Oregon Health and Science University Combination of low dose estrogen and immunotherapeutic agent for treating immune diseases
US6972187B2 (en) 2000-05-12 2005-12-06 Millennium Pharmaceuticals, Inc. OAT5 molecules and uses therefor
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
US6571638B2 (en) 2000-06-30 2003-06-03 Sawtek, Inc. Surface-acoustic-wave pressure sensor and associated methods
AU2001277857A1 (en) 2000-07-07 2002-01-21 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
DE60121346T8 (de) 2000-08-04 2007-12-13 Ludwig Institute For Cancer Research Suppressor-Gen
US20020019837A1 (en) 2000-08-11 2002-02-14 Balnaves James A. Method for annotating statistics onto hypertext documents
US6824989B1 (en) 2000-09-01 2004-11-30 Upstate Biotechnology, Inc. Recombinant monoclonal antibody to phosphotyrosine-containing proteins
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20020048566A1 (en) 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
WO2002028999A2 (en) 2000-10-03 2002-04-11 Gene Logic, Inc. Gene expression profiles in granulocytic cells
USH2191H1 (en) 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
JP3898126B2 (ja) 2000-10-24 2007-03-28 俊一 塩澤 慢性関節リウマチに関与するゲノム、その診断方法、その発症可能性の判定方法、それらの検出用診断キットおよび、慢性関節リウマチの治療方法ならびに治療薬剤
CA2427471C (en) 2000-10-30 2010-12-21 The Regents Of The University Of Michigan Nod2 nucleic acids and proteins
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US20040072154A1 (en) 2000-12-22 2004-04-15 Morris David W. Novel compositions and methods for cancer
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
US20020182274A1 (en) 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
US20050182007A1 (en) 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050261219A1 (en) 2001-05-18 2005-11-24 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
CA2391711A1 (en) 2001-06-26 2002-12-26 University Of Guelph Non-radioactive assay of lipopolysaccharide kinases
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003025148A2 (en) 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
GB0124315D0 (en) 2001-10-10 2001-11-28 Oxagen Ltd Inflammatory bowel disease
JP5236856B2 (ja) 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
US7767390B2 (en) 2001-11-20 2010-08-03 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
FI20020078A7 (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6878518B2 (en) 2002-01-22 2005-04-12 The Trustees Of The University Of Pennsylvania Methods for determining steroid responsiveness
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US7745180B2 (en) 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
AU2003232872A1 (en) 2002-05-27 2003-12-12 Ostergotlands Lans Landsting Method for determining immune system affecting compounds
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
TW200409759A (en) 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
SI2301965T1 (sl) 2002-10-16 2015-07-31 Purdue Pharma L.P. Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
JP2006517916A (ja) 2002-10-30 2006-08-03 ザ シービーアール インスティテュート フォー バイオメディカル リサーチ インコーポレーティッド Ｒｎａ干渉物質を用いてアポトーシス関連疾患を治療および予防する方法
AU2003298703A1 (en) 2002-11-22 2004-06-18 Emory University Diagnostic tests and methods for diagnosing inflammatory bowel disease
AU2003293096B9 (en) 2002-11-27 2011-09-29 Biogen Ma Inc. Humanized antibodies against monocyte chemotactic proteins
CA2506672C (en) 2002-12-23 2012-04-17 Schering Corporation Il-23 for treating cutaneous wounds
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
US20070020637A1 (en) 2003-01-21 2007-01-25 Research Association For Biotechnology Full-length cDNA
US8071304B2 (en) 2003-04-05 2011-12-06 The Johns Hopkins University Methods for detecting a polymorphism in the NFKB1 gene promoter
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
WO2004109288A1 (en) 2003-06-06 2004-12-16 Astrazeneca Ab Method for diagnosing inflammatory bowel disease
ES2428321T3 (es) 2003-08-20 2013-11-07 University Of Miami Composiciones y métodos para tratar la enfermedad del pulmón inflamado
WO2005018436A2 (en) 2003-08-26 2005-03-03 The Trustees Of Boston University Methods for the diagnosis, prognosis and treatment of metabolic syndrome
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US20070161003A1 (en) 2003-09-29 2007-07-12 Morris David W Novel therapeutic targets in cancer
US20050101889A1 (en) 2003-11-06 2005-05-12 Freeman Gary A. Using chest velocity to process physiological signals to remove chest compression artifacts
US20070054278A1 (en) 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
WO2005054853A2 (en) 2003-12-03 2005-06-16 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies
WO2005068664A2 (en) 2004-01-09 2005-07-28 The Regents Of The University Of California Cell-type-specific patterns of gene expression
WO2005071059A2 (en) 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
CA2562771C (en) 2004-04-12 2013-04-09 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
WO2005114469A1 (fr) 2004-04-19 2005-12-01 Kartoo Sa Procede et dispositif de recherche avec conservation personnalisee des resultats
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7759079B2 (en) 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7407753B2 (en) 2004-05-24 2008-08-05 Yissum Research Development Company Of The Hebrewuniversityofjerusalem Methods, kits and pharmaceutical compositions for diagnosing, delaying onset of, preventing and/or treating osteoporosis
CN101426930A (zh) 2004-05-25 2009-05-06 日立化成工业株式会社 检测癌症易感性的方法
US20080287309A1 (en) 2004-07-10 2008-11-20 Alexion Pharmaceuticals, Inc. Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
WO2006020430A2 (en) 2004-08-12 2006-02-23 Genentech, Inc. Novel composition and methods for the treatment of immune related disease
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
WO2006045318A2 (en) 2004-10-27 2006-05-04 Aarhus Universitet Diagnosis and treatment of immune-related diseases
WO2006048291A2 (en) 2004-11-03 2006-05-11 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
WO2008101133A2 (en) 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
WO2008109782A2 (en) 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
AU2005314089B2 (en) 2004-12-08 2011-03-03 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
EP1836322B8 (en) 2005-01-13 2017-01-11 Progenika Biopharma, S.A. Methods and products for in vitro genotyping
US8110347B2 (en) 2005-04-15 2012-02-07 Canimguide Therapeutics Ab Diagnostic method for detecting cancer by measuring amount of cytokine like IL-6
WO2006116721A1 (en) 2005-04-28 2006-11-02 Hitachi Chemical Research Center, Inc. Ex vivo gene expression in whole blood as a model of assessment of individual variation to dietary supplements
US7531637B2 (en) * 2005-05-06 2009-05-12 Zymogenetics, Inc. IL-31 monoclonal antibodies
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
ES2301280A1 (es) 2005-05-16 2008-06-16 Fina Biotech S.L.U. Metodo para diagnosticar la enfermedad de alzheimer.
US20090317388A1 (en) * 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
BRPI0611714A2 (pt) 2005-06-30 2009-01-13 Abbott Lab proteÍnas de ligaÇço a il-12/p40
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101253199B (zh) 2005-08-30 2019-06-14 迈阿密大学 免疫调节肿瘤坏死因子受体25(tnfr25)的激动剂、拮抗剂和免疫毒素
WO2007025989A2 (en) 2005-09-02 2007-03-08 Innogenetics N.V. Nucleic acid variants in the toll like receptor genes associated with altered innate immunity
CA2624359A1 (en) 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
US8234129B2 (en) 2005-10-18 2012-07-31 Wellstat Vaccines, Llc Systems and methods for obtaining, storing, processing and utilizing immunologic and other information of individuals and populations
US20090258848A1 (en) 2005-12-06 2009-10-15 The Johns Hopkins University Biomarkers for inflammatory bowel disease
US20070161031A1 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
JP2009526756A (ja) * 2006-01-10 2009-07-23 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法
US20100019016A1 (en) 2006-03-23 2010-01-28 Edoga John K Vascular Anastomotic Staplers
EP2005175B1 (en) 2006-04-07 2011-07-27 Hitachi Chemical Company, Ltd. Enhanced t cell receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with crohn's disease
US20100041600A1 (en) 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
WO2008014400A2 (en) 2006-07-26 2008-01-31 Genizon Biosciences Inc. Crohn disease susceptibility gene
WO2008021431A2 (en) 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
WO2008028031A2 (en) 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel
EP2639319B1 (en) 2006-09-11 2015-07-08 Celera Corporation Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2008048902A2 (en) 2006-10-13 2008-04-24 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease
US20100267575A1 (en) 2006-10-17 2010-10-21 Childrens Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
WO2008048984A2 (en) 2006-10-18 2008-04-24 St. Jude Children's Research Hospital Methods and compositions for preparing a universal influenza vaccine
US20100291551A1 (en) 2006-11-17 2010-11-18 Genizon Biosciences Inc. Genemap of the human associated with crohn's disease
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
WO2008073303A2 (en) 2006-12-07 2008-06-19 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods
US20090186034A1 (en) 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008106579A2 (en) 2007-02-28 2008-09-04 Cedars-Sinai Medical Center The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
US20150337378A1 (en) 2007-02-28 2015-11-26 Cedars-Sinai Medical Center Methods of diagnosis and treatment of inflammatory bowel disease
JP2010519895A (ja) 2007-03-02 2010-06-10 ユニヴェルシト ド リエージュ クローン病座位における遺伝子型を決定する方法
EP2132338A1 (en) 2007-03-06 2009-12-16 Eesti Biokeskus A method to determine single nucleotide polymorphisms and mutations in nucleic acid sequence
WO2008112990A2 (en) 2007-03-15 2008-09-18 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US8153443B2 (en) 2007-05-10 2012-04-10 Cedars-Sinai Medical Center Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease
WO2012135144A2 (en) 2011-03-25 2012-10-04 Cedars-Sinai Medical Center Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease
WO2011088237A1 (en) 2010-01-13 2011-07-21 Cedars-Sinai Medical Center Methods of using znf365 genetic variants to diagnose crohn's disease
US20150376707A1 (en) 2007-05-18 2015-12-31 Cedars-Sinai Medical Center Methods of diagnosing and treating inflammatory bowel disease
WO2010083234A1 (en) 2009-01-13 2010-07-22 Cedars-Sinai Medical Center Methods of using smad3 and jak2 genetic variants to diagnose and predict inflammatory bowel disease
US9305137B1 (en) 2007-05-18 2016-04-05 Cedars-Sinai Medical Center Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
CA2686686A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc Il-9 in fibrotic and inflammatory disease
WO2012135146A2 (en) 2011-03-25 2012-10-04 Cedars-Sinai Medical Center Role of ifng methylation in inflammatory bowel disease
US20150086567A1 (en) 2011-03-25 2015-03-26 Cedars-Sinai Medical Center Role of ifng methylation in inflammatory bowel disease
US20120190698A1 (en) 2011-01-25 2012-07-26 Cedars-Sinai Medical Center Methods of predicting thiopurine response
CN101821408A (zh) 2007-08-09 2010-09-01 奥塔戈大学 鉴别个体处于硫代嘌呤药物抗性和不耐受性风险的方法
AU2008304205B8 (en) 2007-09-26 2014-08-28 Navigenics, Inc. Methods and systems for genomic analysis using ancestral data
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
US8263743B2 (en) 2007-11-13 2012-09-11 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against TL1A
US7947451B2 (en) 2007-11-30 2011-05-24 Celera Corporation Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
CN101469270B (zh) 2007-12-27 2012-08-22 牛斌 工业连续化塑料裂解器
US7773519B2 (en) 2008-01-10 2010-08-10 Nuova Systems, Inc. Method and system to manage network traffic congestion
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
SI2257643T1 (sl) 2008-02-19 2018-12-31 The Children's Hospital Of Philadelphia Identifikacija predelov vnetne črevesne bolezni z začetkom v otroštvu in metode za njeno uporabo za diagnozo in zdravljenje te bolezni
US20090307181A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009143278A2 (en) 2008-05-20 2009-11-26 Cedars-Sinai Medical Center Methods of diagnosing and characterizing cannabinoid signaling in crohn's disease
WO2010008858A1 (en) 2008-06-23 2010-01-21 Cedars-Sinai Medical Center Use of iron-related pathways and genes for treatment and diagnosis of parkinson's disease
US20100008934A1 (en) 2008-07-02 2010-01-14 Celera Corporation Genetic polymorphisms associated with autoinflammatory diseases, methods of detection and uses thereof
NZ590988A (en) 2008-08-25 2012-08-31 Janssen Biotech Inc Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
US20110136113A1 (en) 2008-08-27 2011-06-09 Sysmex Corporation Marker for detecting il-17-producing helper t cell, and method for detecting il-17-producing helper t cell
US20110159011A1 (en) 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
JP2010088432A (ja) 2008-09-09 2010-04-22 Kansetsu Saisei Kenkyusho:Kk Ｔｎｆ阻害薬治療による有効性・副作用発現に関する多型、およびその利用
ES2493042T3 (es) 2008-09-29 2014-09-11 Roche Glycart Ag Anticuerpos contra la IL-17 humana y usos de los mismos
US20110177969A1 (en) 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
CN102203285B (zh) 2008-10-21 2014-12-31 宋清 利用单倍切割确定单倍型的方法
US20110189685A1 (en) 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20100129838A1 (en) 2008-11-11 2010-05-27 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
US20170044615A1 (en) 2008-12-24 2017-02-16 Cedars-Sinai Medical Center METHODS OF PREDICTING MEDICALLY REFRACTIVE ULCERATIVE COLITIS (mrUC) REQUIRING COLECTOMY
WO2015168699A1 (en) 2014-05-02 2015-11-05 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mruc) requiring colectomy
WO2010075584A1 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of diagnosing and predicting crohns disease from childhood hygiene and serological profiles
RU2542394C2 (ru) 2009-03-24 2015-02-20 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Гуманизированные антитела против light и их применение
WO2010118210A1 (en) 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
EP2960342A1 (en) 2009-04-14 2015-12-30 Nestec S.A. Inflammatory bowel disease prognostics
CN102724993B (zh) 2009-04-17 2016-04-27 纽约大学 靶向tnf家族受体并拮抗tnf作用的肽、组合物、方法及其用途
JP2011004390A (ja) 2009-05-18 2011-01-06 Canon Inc 撮像装置、撮像システム、及び撮像装置の駆動方法
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2757160A3 (en) 2009-07-20 2014-07-30 Genentech, Inc. Gene expression markers for Crohn's disease
WO2011017120A1 (en) 2009-07-27 2011-02-10 Cedars-Sinai Medical Center Use of ccr9, ccl25, batf and il17/il23 pathway variants to diagnose and treat inflammatory bowel disease
KR102033276B1 (ko) 2009-08-03 2019-10-16 유니버시티 오브 마이애미 T 조절 세포의 생체 내 확장 방법
WO2011071725A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
US20130136720A1 (en) 2010-01-15 2013-05-30 Cedars-Sinai Medical Center Methods of using fut2 genetic variants to diagnose crohn's disease
WO2011088306A1 (en) 2010-01-15 2011-07-21 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose crohn's disease
WO2011106707A2 (en) 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
US20130012604A1 (en) 2010-03-16 2013-01-10 Cedars-Sinai Medical Center Methods of using prdm1 genetic variants to prognose, diagnose and treat inflammatory bowel disease
RU2013110874A (ru) 2010-08-25 2014-09-27 Ф.Хоффманн-Ля Рош Аг Антитела против il-18r1 и их применения
JP6105472B2 (ja) 2010-09-16 2017-03-29 バリオファルム・アクチェンゲゼルシャフト 抗ｈｕＴＮＦＲ１抗体
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
JP5960707B2 (ja) 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
ES2530175T3 (es) 2011-02-17 2015-02-26 Nestec S.A. Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF
US20140017711A1 (en) 2011-03-25 2014-01-16 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and crohn's disease
EP2709664A4 (en) 2011-05-20 2015-06-10 Us Government BLOCKADE OF TL1A-DR3 INTERACTIONS FOR THE TREATMENT OF T-CELL-MEDIATED DISEASES AND ANTIBODIES THEREOF
LT2714735T (lt) * 2011-06-03 2021-12-10 Xoma Technology Ltd. Tgf beta specifiniai antikūnai
EP2720719A4 (en) 2011-06-15 2015-12-09 Glaxosmithkline Ip No 2 Ltd METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS
CN202109170U (zh) 2011-06-21 2012-01-11 徐毓艺 多座旋转连接装置
US8478890B2 (en) 2011-07-15 2013-07-02 Damaka, Inc. System and method for reliable virtual bi-directional data stream communications with single socket point-to-multipoint capability
US20130129668A1 (en) 2011-09-01 2013-05-23 The Regents Of The University Of California Diagnosis and treatment of arthritis using epigenetics
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
MX2014003689A (es) * 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
EP2769321B1 (en) 2011-10-21 2016-06-01 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
WO2013074833A1 (en) 2011-11-16 2013-05-23 The Board Of Trustees Of The Leland Stanford Junior University Capture probe and assay for analysis of fragmented nucleic acids
KR20140097336A (ko) 2011-11-23 2014-08-06 암젠 인크 인터페론 감마에 대한 항체를 이용한 치료 방법
BR112014019399A2 (pt) * 2012-02-09 2017-07-04 Nogra Pharma Ltd métodos de tratamento da fibrose
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
SG11201505186SA (en) 2013-01-02 2015-07-30 Glenmark Pharmaceuticals Sa Antibodies that bind to tl1a and their uses
CN103149371B (zh) 2013-02-26 2015-12-23 哈药慈航制药股份有限公司 生物标记物在制备预测5-氨基水杨酸治疗溃疡性结肠炎的反馈响应药物中的应用
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US10633449B2 (en) 2013-03-27 2020-04-28 Cedars-Sinai Medical Center Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
WO2014186665A2 (en) 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
KR20230093538A (ko) 2013-05-17 2023-06-27 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
JP2016536002A (ja) 2013-09-06 2016-11-24 セダーズ−シナイ メディカル センター 抗ｔｌ１ａ療法のためのシステム、デバイス、及び方法
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
SG11201602671WA (en) 2013-11-13 2016-05-30 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
JP2017514837A (ja) 2014-05-02 2017-06-08 テバ ファーマシューティカル インダストリーズ リミティド 遅延放出性６−メルカプトプリンによるクローン病の治療
US20150376612A1 (en) 2014-06-10 2015-12-31 The General Hospital Corporation CCCTC-Binding Factor (CTCF) RNA Interactome
TWI757803B (zh) 2014-11-14 2022-03-11 瑞士商赫孚孟拉羅股份公司 包含tnf家族配位三聚體之抗原結合分子
US20180051078A1 (en) 2015-03-16 2018-02-22 Cedars-Sinai Medical Center Methods of treating inflammatory bowel disease with ifn-gamma therapy
US20180305689A1 (en) 2015-04-22 2018-10-25 Mina Therapeutics Limited Sarna compositions and methods of use
US20180156781A1 (en) 2015-05-15 2018-06-07 Cedars-Sinai Medical Center Models, methods and compositions for treating inflammatory bowel disease
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
WO2017077715A1 (en) 2015-11-02 2017-05-11 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
CA3023678A1 (en) 2016-05-09 2017-11-16 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
ES2994244T3 (en) 2016-07-25 2025-01-21 Cephalon Llc Affinity chromatography wash buffer
JP7194104B2 (ja) 2016-10-26 2022-12-21 シーダーズ―シナイ メディカル センター 抗ｔｌ１ａモノクローナル抗体の中和

Also Published As

Publication number Publication date
US20200190203A1 (en) 2020-06-18
CN105246501A (zh) 2016-01-13
KR20210157418A (ko) 2021-12-28
KR20230109779A (ko) 2023-07-20
JP2022132362A (ja) 2022-09-08
JP6671276B2 (ja) 2020-03-25
BR112015024752A2 (pt) 2017-07-18
EP4285988A3 (en) 2024-03-06
AU2014241162A1 (en) 2015-10-22
WO2014160883A1 (en) 2014-10-02
CN105246501B (zh) 2021-01-12
CA2908553A1 (en) 2014-10-02
US20230091596A1 (en) 2023-03-23
EP2978440B1 (en) 2019-10-02
US10633449B2 (en) 2020-04-28
JP2025078661A (ja) 2025-05-20
JP2020033379A (ja) 2020-03-05
US11434296B2 (en) 2022-09-06
EP3639841A1 (en) 2020-04-22
EP3639841B1 (en) 2023-09-06
EP4285988A2 (en) 2023-12-06
CN112870368A (zh) 2021-06-01
EP2978440A4 (en) 2017-01-18
KR102343212B1 (ko) 2021-12-23
CL2015002866A1 (es) 2016-08-05
US20160060335A1 (en) 2016-03-03
EP2978440A1 (en) 2016-02-03
KR20150134393A (ko) 2015-12-01
KR20240122922A (ko) 2024-08-13
JP2016522164A (ja) 2016-07-28

Similar Documents

Publication Publication Date Title
MX2015013703A (es) Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas.
ZA202208792B (en) Methods of treating and preventing graft versus host disease
PH12016500649A1 (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX381283B (es) Tratamiento de pénfigo.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12013502487A1 (en) Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
MY199027A (en) Method for treating or preventing ophthalmological conditions
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2015017035A (es) Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
MX394452B (es) Inhibicion de la actividad de olig2.
PH12012501389A1 (en) Hedgehog inhibitors
MX2017008462A (es) Metodos para utilizar oligonucleotidos antisentido para smad7.
ZA201901367B (en) Inhibition of olig2 activity
MY205171A (en) Methods of treatment of hypertriglyceridemia
MX2020001759A (es) Inhibidores de histona acetiltransferasa de la familia myst.
PH12014501044B1 (en) Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells